Contineum Therapeutics, Inc. Share Price & Technical Analysis
CTNM · $13.86 (-3.55%)
Healthcare / Biotechnology
$13.86
-3.55%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibro…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 3 years shown)
5% return in May, -6% avg return in past 3 year May month.
22% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 25% | 7% | -13% | -2% | 5% | – | – | – | – | – | – | – | 22% |
| 25 | -34% | -26% | 0% | -41% | -10% | 5% | 51% | 79% | 13% | -5% | 1% | 5% | 38% |
| 24 | – | – | – | 8% | -3% | 10% | 14% | -3% | -5% | -13% | -13% | -1% | -7% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$508.83M
P/E ratio
—
52W high
$16.33
52W low
$3.35
Volume
2,20,306
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Contineum Therapeutics, Inc. share price today?
- Contineum Therapeutics, Inc. (CTNM) last traded around $13.86 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CTNM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CTNM. Download the app for real-time alerts.
- How can I analyze Contineum Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.